questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Lipoprotéines
Apolipoprotéines
Apolipoprotéines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Apolipoprotéines
Tests de laboratoire
Apolipoprotéines
Analyse sanguine
Maladies cardiovasculaires
Apolipoprotéines
Imagerie médicale
Apolipoprotéines
Athérosclérose
Apolipoprotéines
Symptômes
5
Douleur thoracique
Apolipoprotéines
Métabolisme lipidique
Apolipoprotéines
Cholestérol
Apolipoprotéines
Accident vasculaire cérébral
Apolipoprotéines
Prévention
5
Prévention
Apolipoprotéines
Tabagisme
Apolipoprotéines
Contrôle de santé
Apolipoprotéines
Hydratation
Apolipoprotéines
Traitements
5
Statines
Apolipoprotéines
Médicaments hypolipémiants
Apolipoprotéines
Régime alimentaire
Apolipoprotéines
Exercice physique
Apolipoprotéines
Médecine complémentaire
Apolipoprotéines
Complications
5
Maladies cardiovasculaires
Apolipoprotéines
Maladies hépatiques
Apolipoprotéines
Santé rénale
Apolipoprotéines
Inflammation
Apolipoprotéines
Facteurs de risque
5
Hérédité
Apolipoprotéines
Vieillissement
Apolipoprotéines
Mode de vie sédentaire
Apolipoprotéines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines : Questions médicales les plus fréquentes",
"headline": "Apolipoprotéines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Apolipoprotéines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Lipoprotéines",
"url": "https://questionsmedicales.fr/mesh/D008074",
"about": {
"@type": "MedicalCondition",
"name": "Lipoprotéines",
"code": {
"@type": "MedicalCode",
"code": "D008074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines M",
"alternateName": "Apolipoproteins M",
"url": "https://questionsmedicales.fr/mesh/D000075243",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines M",
"code": {
"@type": "MedicalCode",
"code": "D000075243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines A",
"alternateName": "Apolipoproteins A",
"url": "https://questionsmedicales.fr/mesh/D001054",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines A",
"code": {
"@type": "MedicalCode",
"code": "D001054",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-I",
"alternateName": "Apolipoprotein A-I",
"url": "https://questionsmedicales.fr/mesh/D016632",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-I",
"code": {
"@type": "MedicalCode",
"code": "D016632",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-II",
"alternateName": "Apolipoprotein A-II",
"url": "https://questionsmedicales.fr/mesh/D016633",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-II",
"code": {
"@type": "MedicalCode",
"code": "D016633",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine A-V",
"alternateName": "Apolipoprotein A-V",
"url": "https://questionsmedicales.fr/mesh/D000072040",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine A-V",
"code": {
"@type": "MedicalCode",
"code": "D000072040",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.200.575"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines B",
"alternateName": "Apolipoproteins B",
"url": "https://questionsmedicales.fr/mesh/D001055",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines B",
"code": {
"@type": "MedicalCode",
"code": "D001055",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-48",
"alternateName": "Apolipoprotein B-48",
"url": "https://questionsmedicales.fr/mesh/D053283",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-48",
"code": {
"@type": "MedicalCode",
"code": "D053283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.240"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine B-100",
"alternateName": "Apolipoprotein B-100",
"url": "https://questionsmedicales.fr/mesh/D053299",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine B-100",
"code": {
"@type": "MedicalCode",
"code": "D053299",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.300.249"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines C",
"alternateName": "Apolipoproteins C",
"url": "https://questionsmedicales.fr/mesh/D001056",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines C",
"code": {
"@type": "MedicalCode",
"code": "D001056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-I",
"alternateName": "Apolipoprotein C-I",
"url": "https://questionsmedicales.fr/mesh/D053302",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-I",
"code": {
"@type": "MedicalCode",
"code": "D053302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-II",
"alternateName": "Apolipoprotein C-II",
"url": "https://questionsmedicales.fr/mesh/D053304",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-II",
"code": {
"@type": "MedicalCode",
"code": "D053304",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine C-III",
"alternateName": "Apolipoprotein C-III",
"url": "https://questionsmedicales.fr/mesh/D053305",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine C-III",
"code": {
"@type": "MedicalCode",
"code": "D053305",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.400.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines D",
"alternateName": "Apolipoproteins D",
"url": "https://questionsmedicales.fr/mesh/D053399",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines D",
"code": {
"@type": "MedicalCode",
"code": "D053399",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines E",
"alternateName": "Apolipoproteins E",
"url": "https://questionsmedicales.fr/mesh/D001057",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines E",
"code": {
"@type": "MedicalCode",
"code": "D001057",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E2",
"alternateName": "Apolipoprotein E2",
"url": "https://questionsmedicales.fr/mesh/D053329",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E2",
"code": {
"@type": "MedicalCode",
"code": "D053329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E3",
"alternateName": "Apolipoprotein E3",
"url": "https://questionsmedicales.fr/mesh/D053318",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E3",
"code": {
"@type": "MedicalCode",
"code": "D053318",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine E4",
"alternateName": "Apolipoprotein E4",
"url": "https://questionsmedicales.fr/mesh/D053327",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine E4",
"code": {
"@type": "MedicalCode",
"code": "D053327",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéines L",
"alternateName": "Apolipoproteins L",
"url": "https://questionsmedicales.fr/mesh/D000075943",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines L",
"code": {
"@type": "MedicalCode",
"code": "D000075943",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Apolipoprotéine L1",
"alternateName": "Apolipoprotein L1",
"url": "https://questionsmedicales.fr/mesh/D000075944",
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéine L1",
"code": {
"@type": "MedicalCode",
"code": "D000075944",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.521.120.750.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Apolipoprotéines",
"alternateName": "Apolipoproteins",
"code": {
"@type": "MedicalCode",
"code": "D001053",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Joan Carles Escolà-Gil",
"url": "https://questionsmedicales.fr/author/Joan%20Carles%20Escol%C3%A0-Gil",
"affiliation": {
"@type": "Organization",
"name": "Institut de Recerca Sant Pau, 08041 Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Robert A Hegele",
"url": "https://questionsmedicales.fr/author/Robert%20A%20Hegele",
"affiliation": {
"@type": "Organization",
"name": "Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Catherine Mounier",
"url": "https://questionsmedicales.fr/author/Catherine%20Mounier",
"affiliation": {
"@type": "Organization",
"name": "Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada."
}
},
{
"@type": "Person",
"name": "Allan Sniderman",
"url": "https://questionsmedicales.fr/author/Allan%20Sniderman",
"affiliation": {
"@type": "Organization",
"name": "Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Alprostadil for hypertensive nephropathy: A systematic review and meta-analysis of randomized controlled trials.",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/35617324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0269111"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of administrative intervention for neurosurgical patients with off-label use of alprostadil lipid microsphere.",
"datePublished": "2022-09-13",
"url": "https://questionsmedicales.fr/article/36100635",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-19717-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of Alprostadil Combined with Edaravone on Inflammation, Oxidative Stress and Pulmonary Function in Patients with Traumatic Hemorrhagic Shock.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36800822",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14715/cmb/2022.68.8.22"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37251365",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2023/4100197"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of Alprostadil for Ductal Patency.",
"datePublished": "2024-02-07",
"url": "https://questionsmedicales.fr/article/38332962",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5863/1551-6776-29.1.37"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D008074"
},
{
"@type": "ListItem",
"position": 5,
"name": "Apolipoprotéines",
"item": "https://questionsmedicales.fr/mesh/D001053"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Apolipoprotéines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Apolipoprotéines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Apolipoprotéines",
"description": "Comment diagnostiquer une anomalie des apolipoprotéines ?\nQuels tests sont utilisés pour évaluer les apolipoprotéines ?\nLes apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?\nPeut-on détecter des apolipoprotéines par imagerie ?\nQuels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Apolipoprotéines",
"description": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?\nLes apolipoprotéines affectent-elles le métabolisme ?\nComment les apolipoprotéines influencent-elles le cholestérol ?\nDes symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?\nLes apolipoprotéines sont-elles liées à l'obésité ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Apolipoprotéines",
"description": "Comment prévenir les anomalies d'apolipoprotéines ?\nLe tabagisme influence-t-il les apolipoprotéines ?\nLe stress a-t-il un impact sur les apolipoprotéines ?\nLes contrôles réguliers de santé sont-ils importants ?\nL'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Apolipoprotéines",
"description": "Quels traitements existent pour les anomalies d'apolipoprotéines ?\nLes médicaments peuvent-ils normaliser les apolipoprotéines ?\nLe régime alimentaire influence-t-il les apolipoprotéines ?\nLes exercices physiques affectent-ils les niveaux d'apolipoprotéines ?\nLes traitements naturels peuvent-ils aider les apolipoprotéines ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Apolipoprotéines",
"description": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?\nLes apolipoprotéines anormales peuvent-elles causer des diabètes ?\nLes troubles hépatiques sont-ils liés aux apolipoprotéines ?\nLes apolipoprotéines affectent-elles la santé rénale ?\nLes apolipoprotéines peuvent-elles influencer l'inflammation ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Apolipoprotéines",
"description": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?\nL'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?\nLe vieillissement influence-t-il les niveaux d'apolipoprotéines ?\nLe sexe a-t-il un impact sur les apolipoprotéines ?\nLe mode de vie sédentaire est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D001053?mesh_terms=Alprostadil#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des apolipoprotéines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'apolipoprotéines sont effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les apolipoprotéines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages des apolipoprotéines A1 et B sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées aux maladies cardiovasculaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux d'apolipoprotéines sont associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des apolipoprotéines par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la détection se fait principalement par des analyses sanguines, pas par imagerie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème d'apolipoprotéines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'athérosclérose peuvent indiquer des anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés d'apolipoprotéines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés peuvent entraîner des douleurs thoraciques ou des crises cardiaques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle clé dans le métabolisme lipidique et peuvent causer des troubles."
}
},
{
"@type": "Question",
"name": "Comment les apolipoprotéines influencent-elles le cholestérol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles transportent le cholestérol dans le sang, influençant les niveaux de cholestérol total."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils être liés aux apolipoprotéines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être associées à des troubles neurologiques comme l'AVC."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines sont-elles liées à l'obésité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être observés chez les personnes obèses."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies d'apolipoprotéines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain avec une alimentation équilibrée et de l'exercice régulier."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les apolipoprotéines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque d'anomalies d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les apolipoprotéines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers de santé sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans de santé réguliers aident à détecter les anomalies tôt."
}
},
{
"@type": "Question",
"name": "L'hydratation joue-t-elle un rôle dans la santé des apolipoprotéines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une bonne hydratation est essentielle pour le métabolisme lipidique."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les anomalies d'apolipoprotéines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines et les changements de mode de vie sont souvent recommandés."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils normaliser les apolipoprotéines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aider à réguler les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il les apolipoprotéines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un régime riche en fibres et faible en graisses saturées peut aider."
}
},
{
"@type": "Question",
"name": "Les exercices physiques affectent-ils les niveaux d'apolipoprotéines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer les niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Les traitements naturels peuvent-ils aider les apolipoprotéines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes et suppléments peuvent soutenir la santé lipidique, mais consultez un médecin."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des apolipoprotéines anormales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies cardiovasculaires, des AVC et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines anormales peuvent-elles causer des diabètes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont liées à un risque accru de diabète de type 2."
}
},
{
"@type": "Question",
"name": "Les troubles hépatiques sont-ils liés aux apolipoprotéines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être associés à des maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines affectent-elles la santé rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Les apolipoprotéines peuvent-elles influencer l'inflammation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés sont souvent associés à des états inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les anomalies d'apolipoprotéines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme, une mauvaise alimentation et le manque d'exercice sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les anomalies d'apolipoprotéines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiovasculaires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le vieillissement influence-t-il les niveaux d'apolipoprotéines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut entraîner des modifications des niveaux d'apolipoprotéines."
}
},
{
"@type": "Question",
"name": "Le sexe a-t-il un impact sur les apolipoprotéines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des différences hormonales peuvent influencer les niveaux d'apolipoprotéines entre les sexes."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire augmente le risque d'anomalies d'apolipoprotéines."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institut de Recerca Sant Pau, 08041 Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
3 publications dans cette catégorie
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Laboratoire du Métabolisme Moléculaire des Lipides, Université du Québec à Montréal, Département des Sciences Biologiques, Case Postale 8888, Succursale Centre-ville, Montréal, QC H3C 3P8, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Mental Health and Society Division, Douglas Mental Health University Institute, Montreal, QC, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Institute of Mental Health, Hebei Mental Health Centre, Hebei, China. yunshucoffee@sina.com.
Department of Sleep Medicine, Hebei Psychiatric Hospital, Hebei, China. yunshucoffee@sina.com.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16 Lin Cui Road, Beijing, 100101, China. zhangxy@psych.ac.cn.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Neurology University of Kansas Medical Center, Kansas City, KS 66160, USA.
University of Kansas Alzheimer's Disease Center, Kansas City, KS 66160, USA.
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Department of Biochemistry, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology & Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada; Robarts Research Institute, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada. Electronic address: mlk@robarts.ca.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
School of Public Health, Guangdong Medical University, Zhanjiang, 524023, China.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Public Health Foundation India, Gurugram, Haryana, India; Centre for Chronic Disease Control, New Delhi, India; London School of Hygiene & Tropical Medicine, United Kingdom. Electronic address: dprabhakaran@ccdcindia.org.
Publications dans "Apolipoprotéines" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China.
Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Center for Biomedical Research (CEBIOR), Faculty of Medicine, Universitas Diponegoro, Semarang 50275, Central Java, Indonesia.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Department of Psychology, University of Marlyand, College Park, MD 20742, USA.
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
MIND Institute, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Publications dans "Apolipoprotéines" :
1 publication dans cette catégorie
Affiliations :
Division of Biostatistics, School of Medicine, University of California Davis, Davis, CA 95616, USA.
Publications dans "Apolipoprotéines" :
We performed a meta-analysis to evaluate the efficacy of alprostadil in the treatment of hypertensive nephropathy. Seven online databases (PubMed, Embase, Cochrane Library, China National Knowledge In...
As an adjuvant drug, alprostadil lipid microsphere injection (Lipo-PGE...
The study aimed to explore the roles of alprostadil combined with edaravone in inflammation, oxidative stress and Pulmonary function in patients with traumatic hemorrhagic shock (HS). 80 patients with...
In-stent restenosis (ISR) is a common complication after percutaneous coronary intervention (PCI) surgery for patients with coronary atherosclerotic heart disease (CHD). Reports indicate alprostadil m...
Articles were searched from databases, and meta-analysis was performed in Review Manager software. Funnel plots were performed to evaluate the publication bias, and sensitivity analysis was performed ...
Initially, 113 articles were identified, and 5 studies of 463 subjects were included for analysis eventually. The primary endpoint, i.e., the occurrence of ISR after PCI, occurred in 11.91% of the alp...
This study aims to describe the effectiveness of low initial alprostadil dosages to maintain a patent ductus arteriosus (PDA) in infants with ductal-dependent congenital heart disease (DDCHD). Seconda...
This retrospective observational cohort study at the British Columbia's Women's and Children's Hospital neonatal intensive care unit and pediatric intensive care unit examined neonates admitted with D...
Alprostadil was effective for 88% of patients, with no difference between the very low-dose and low-dose groups. Of the 75 patients included, 25 received very low-dose alprostadil. Adverse drug events...
Alprostadil therapy was effective in maintaining the PDA in neonates with DDCHD with low-dosage regimens. Adverse drug events were common with both dosage regimens; however, the very low dosage appear...
The aim is to investigate the clinical efficacy of Alprostadil in diabetes mellitus (DM) combined with peripheral atherosclerosis and to investigate the molecular mechanisms....
Patients included 154 cases with DM combined with peripheral atherosclerosis and were divided into the conventional group (77 cases) and the Alprostadil group (77 cases). Both groups of patients were ...
The total effective rate of treatment in the Alprostadil group was higher than that in the conventional group. The biochemical indices of whole blood viscosity, plasma viscosity, erythrocyte pressure ...
Clinically, the use of Alprostadil as an adjunct to conventional therapy for the treatment of DM combined with peripheral atherosclerosis has high clinical efficacy. In addition, Alprostadil has a sig...
To evaluate the long-term efficacy of transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE) for gastroesophageal reflux disease (GERD)....
A total of 16 patients with proton pump inhibitor-dependent gastroesophageal reflux disease had undergone TIF by MUSE in Shanghai General Hospital (Shanghai, China)from March 2017 to December 2018. Pa...
Follow-up data were collected from 13 patients, ranging from 38 to 63 months, 53 months on average. 10/13 patients reported symptomatic improvement and daily PPI consumption was stopped or halved in 1...
TIF by MUSE has significant efficacy in the treatment of PPI-dependent GERD, which can improve symptoms and life quality of patients, and reduce the acid exposure time for long-term. Chictr.org.cn....
ChiCTR2000034350....
To compare four diffusion-weighted imaging (DWI) sequences for image quality, rectal contour, and lesion conspicuity, and to assess the difference in their signal-to-noise ratio (SNR) and contrast-to-...
In this retrospective study of 36 consecutive patients who underwent 3.0 T rectal MRI from January-June 2020, DWI was performed with single-shot echo planar imaging (ss-EPI) (b800 s/mm...
For both readers, MUSE b800 scored significantly higher for image quality, rectal contour, and lesion conspicuity compared to ss-EPI; MUSE b800 also scored significantly higher for image quality and r...
MUSE b800 improved image quality over ss-EPI and both MUSE b800 and b1500 showed better tumor conspicuity compared to conventional ss-EPI....
We describe an original minimally invasive penile plication technique with scrotal or infrapubic access, not requiring circumcision, for penile curvature of different severity and types. This techniqu...
Between 2012 and 2018 we treated 134 patients suffering from congenital curvature (33) and acquired curvature from Peyronie's disease (101). The average curvature was 62.2° (± 30.4°). Preoperative eva...
Complete correction of penile curvature was achieved in 96.8 % of patients. No major complications were reported, and no patients suffered worsening in erectile function or in penile sensitivity. The ...
This is a simple and rapid technique that perfectly corrects even the most severe and complex penile curvatures. In comparison to traditional techniques, such as Nesbit procedure, this technique is as...
Type 1 interferons play a key role in the pathogenesis of systemic lupus erythematosus (SLE). An important clinical question is whether inhibiting the type 1 interferon pathway reduce the disease acti...
Key terms (SLE, type 1 interferon, anifrolumab) were used to query the PubMed database for phase 1, 2 and 3 clinical trials of anifrolumab for SLE patients. Phase 1 studies showed anifrolumab has non-...
Anifrolumab is an exciting new therapeutic for SLE patients. Additional analyses of the combined TULIP-1 and TULIP-2 datasets as well as future studies with anifrolumab will generate yet more data in ...